TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent of patients in sinus rhythm at day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time from cord clamping to positioning under radiant warmer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First urine output time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Erythropoietin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: YMRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episode duration
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: C2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental integrated postprandial motilin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: solid emptying at 120 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: total social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: independence-competence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: independence-performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Nutrition knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy expectations regarding healthy eating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of DP-b99
Endpoint domain: Adverse events/effects
Primary endpoint: Subsequent emetic events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of upper gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: good quality embryo rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive change after 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: carotid atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risperidone area under the curve (AUC(0‐48))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal concentration (C(max)) of risperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic diagnosis of funisitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Newborn requirements for neonatal intensive care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduction of adolescent depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of ART adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients dead or dependent
Endpoint domain: Mortality/survival
Primary endpoint: Excessive daytime sleepiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: milk production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: access time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical remission based on DAS28-CRP at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic progression at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Documentation of complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of S. mutans colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cognitive development improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor development improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta 2-microglobulin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Response rate to phenelzine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dextrose requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: visual analog scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: minimal cross‐sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma urocortin 1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Posttreatment PSADT > 150% of baseline PSADT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathogen eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reintervention rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Respiratory exacerbation requiring intravenous antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: locoregional recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: failure rate of the shunting device
Endpoint domain: Mortality/survival
Primary endpoint: shunt endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: signs of overdrainage
Endpoint domain: Adverse events/effects
Primary endpoint: reductions in alcohol and drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of remission from substance use disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retention in treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of POCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nurse-recorded NRS correlation with BPI severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Research-recorded NRS correlation with BPI severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain underestimation due to qualitative rating
Endpoint domain: Adverse events/effects
Primary endpoint: Post-stroke emotional incontinence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-stroke depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Age at onset of first manifestation of MIDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ease of fetal extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uterine tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Mean reduction in total MSHQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in CGI-I scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Superficial skin blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Development of HAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean frequency of uterine contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: thyroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in PI, GI, SBI, and PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gains in PAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe choices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quality and depth of nighttime sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: number of nighttime awakenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Small artery compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intraperitoneal cancer cell spillage
Endpoint domain: Adverse events/effects
Primary endpoint: Meeting WHO physical activity recommendation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: arterial stiffness index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of HbA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of PD (Pocket Depth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of AL (Attachment Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal airflow improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of leucocyte infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Skin eruptions
Endpoint domain: Adverse events/effects
Primary endpoint: Drug hypersensitivity confirmed by OPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone remodeling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matrix mineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mineralization heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital Capacity Measurement Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Local activation times (LAT) of the high posterior wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-tonsillectomy pain when swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women remaining asymptomatic
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin Blood Flow (SBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular Blood Volume (MBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupil Diameter (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month CDW free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month CDI achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEDA proportions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on the final SAQ test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: SpO2 at peak etCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Restoration of bowel sound within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tolerance to enteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Defecation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CSF concentrations of MCP‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CSF concentrations of MMP‐9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Achievement of HbA1c <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: psychological support needs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: T2D incidence
Endpoint domain: Mortality/survival
Primary endpoint: stroke risk
Endpoint domain: Mortality/survival
Primary endpoint: mean stride length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of BT-A injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of CDU for endoleak detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of CDU for endoleak detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anterior Knee Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain scores at 4 and 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BFOA failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TM, TS, MS, EPS, %ΔSMH, and ΔKHN values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness against MRSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tolerability in topical applications
Endpoint domain: Adverse events/effects
Primary endpoint: Defect Fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported symptom levels of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: spasm scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nuclear division index (NDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of micronuclei (MN) in mononuclear lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of micronuclei (MN) in binuclear lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of BRS for the upper limb and hand/finger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAL neutrophil percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in epicardial adipose tissue (EAT) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in pericardial adipose tissue (PAT) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gas retention during the gas challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perception of abdominal sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relative abundance of bifidobacteria counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean duration of seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: s-CTX reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: B-ALP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: on time without troubling dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fractional concentration of radioactivity in thyroid tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement of facial nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective rates of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of injuries to the larynx and trachea
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of correct insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Extent of repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in VASI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative mean monocular BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until definitive global health score deterioration
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean catheter time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: relieving urodynamic obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: ASAS 20 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p factor variance in total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: within-person variation in external outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retention at follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median time to onset of block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) for mosapride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-)(t) for mosapride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-∞) for mosapride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved global PSQI scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduction in frequency of hypnotic drug use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Short-term tobacco cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintained cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative recurrence rate after one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of febrile neutropenia (FN) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum D-lactic acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of target feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of BPAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quick Disability of the Arm, Shoulder and Hand score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Duration of orthosis wear
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total cost savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increased knowledge about LARC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive change in attitudes towards LARC
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in usual sedentary activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in percent of time spent in moderate and moderate-to-vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean minimal platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean maximal platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence rate of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of fights resulting in an injury requiring medical treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevention of fecal loading/constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: LSS symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of restorations
Endpoint domain: Mortality/survival
Primary endpoint: Mean increase of new surfaces with cavities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent reduction in inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent reduction in noninflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes